Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × Famotidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma 1 Multiple Myeloma 1 Lymphoma 1 Liposarcoma 1 Histiocytoma, Malignant Fibrous 1 Dermatofibrosarcoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 27 fludarabine 18 Rituximab 16 obinutuzumab 11 venetoclax 9 Lenalidomide 9 Bendamustine Hydrochloride 9 Prednisone 7 zanubrutinib 5 pembrolizumab 5 ibrutinib 5 Exercise 5 Etoposide 5 Doxorubicin 5 Blood Specimen Collection 5 Biopsy 5 fludarabine phosphate 4 Vincristine 4 Mesna 4 Cytarabine 4 tafasitamab 3 loncastuximab tesirine 3 glofitamab 3 axicabtagene ciloleucel 3 acalabrutinib 3 Trimethoprim, Sulfamethoxazole Drug Combination 3 Temozolomide 3 Surveys and Questionnaires 3 Radiotherapy 3 Palliative Care 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03647072 2018-08-27

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Tanta University

Phase 3 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡